0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neuromyelitis Optica Drug Market Insights, Forecast to 2030
Published Date: July 2024
|
Report Code: QYRE-Auto-16A2404
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Neuromyelitis Optica Drug Market Insights and Forecast to 2028
BUY CHAPTERS

Global Neuromyelitis Optica Drug Market Insights, Forecast to 2030

Code: QYRE-Auto-16A2404
Report
July 2024
Pages:114
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Neuromyelitis Optica Drug Market Size

The global Neuromyelitis Optica Drug market is projected to grow from US$ 49 million in 2024 to US$ 58 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.0% during the forecast period.

Neuromyelitis Optica Drug Market

Neuromyelitis Optica Drug Market

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
Market Analysis and Insights: Global Neuromyelitis Optica Drug Market
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
Report Covers:
This report presents an overview of global market for Neuromyelitis Optica Drug market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Neuromyelitis Optica Drug, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Neuromyelitis Optica Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Neuromyelitis Optica Drug revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Neuromyelitis Optica Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Neuromyelitis Optica Drug revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation

Scope of Neuromyelitis Optica Drug Market Report

Report Metric Details
Report Name Neuromyelitis Optica Drug Market
Accounted market size in 2024 US$ 49 million
Forecasted market size in 2030 US$ 58 million
CAGR 3.0
Base Year 2024
Forecasted years 2024 - 2030
Segment by Type
  • Glucocorticoids
  • Immunotherapies
  • Others
Segment by Application
  • Acute Attack
  • Remission Prophylactic Treatment
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Revenue of Neuromyelitis Optica Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Neuromyelitis Optica Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
  • Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
  • Chapter 8: China by Type, and by Application, revenue for each segment.
  • Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
  • Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuromyelitis Optica Drug revenue, gross margin, and recent development, etc.
  • Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

How fast is Neuromyelitis Optica Drug Market growing?

Ans: The Neuromyelitis Optica Drug Market witnessing a CAGR of 3.0 during the forecast period 2024-2030.

What is the Neuromyelitis Optica Drug Market size in 2030?

Ans: The Neuromyelitis Optica Drug Market size in 2030 will be US$ 58 million.

What is the Neuromyelitis Optica Drug Market share by region?

Ans: Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

What is the market share of major companies in Neuromyelitis Optica Drug Market?

Ans: Top 3 companies occupied about 35% market share.

Who are the main players in the Neuromyelitis Optica Drug Market report?

Ans: The main players in the Neuromyelitis Optica Drug Market are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP

What are the Application segmentation covered in the Neuromyelitis Optica Drug Market report?

Ans: The Applications covered in the Neuromyelitis Optica Drug Market report are Acute Attack, Remission Prophylactic Treatment

What are the Type segmentation covered in the Neuromyelitis Optica Drug Market report?

Ans: The Types covered in the Neuromyelitis Optica Drug Market report are Glucocorticoids, Immunotherapies, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Glucocorticoids
1.2.3 Immunotherapies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Acute Attack
1.3.3 Remission Prophylactic Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Drug Market Perspective (2019-2030)
2.2 Global Neuromyelitis Optica Drug Growth Trends by Region
2.2.1 Neuromyelitis Optica Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neuromyelitis Optica Drug Historic Market Size by Region (2019-2024)
2.2.3 Neuromyelitis Optica Drug Forecasted Market Size by Region (2025-2030)
2.3 Neuromyelitis Optica Drug Market Dynamics
2.3.1 Neuromyelitis Optica Drug Industry Trends
2.3.2 Neuromyelitis Optica Drug Market Drivers
2.3.3 Neuromyelitis Optica Drug Market Challenges
2.3.4 Neuromyelitis Optica Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Neuromyelitis Optica Drug by Players
3.1.1 Global Neuromyelitis Optica Drug Revenue by Players (2019-2024)
3.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2019-2024)
3.2 Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Neuromyelitis Optica Drug, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Neuromyelitis Optica Drug Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Drug Revenue in 2023
3.5 Global Key Players of Neuromyelitis Optica Drug Head office and Area Served
3.6 Global Key Players of Neuromyelitis Optica Drug, Product and Application
3.7 Global Key Players of Neuromyelitis Optica Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuromyelitis Optica Drug Breakdown Data by Type
4.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2019-2024)
4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2025-2030)
5 Neuromyelitis Optica Drug Breakdown Data by Application
5.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2019-2024)
5.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neuromyelitis Optica Drug Market Size (2019-2030)
6.2 North America Neuromyelitis Optica Drug Market Size by Type
6.2.1 North America Neuromyelitis Optica Drug Market Size by Type (2019-2024)
6.2.2 North America Neuromyelitis Optica Drug Market Size by Type (2025-2030)
6.2.3 North America Neuromyelitis Optica Drug Market Share by Type (2019-2030)
6.3 North America Neuromyelitis Optica Drug Market Size by Application
6.3.1 North America Neuromyelitis Optica Drug Market Size by Application (2019-2024)
6.3.2 North America Neuromyelitis Optica Drug Market Size by Application (2025-2030)
6.3.3 North America Neuromyelitis Optica Drug Market Share by Application (2019-2030)
6.4 North America Neuromyelitis Optica Drug Market Size by Country
6.4.1 North America Neuromyelitis Optica Drug Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Neuromyelitis Optica Drug Market Size by Country (2019-2024)
6.4.3 North America Neuromyelitis Optica Drug Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Drug Market Size (2019-2030)
7.2 Europe Neuromyelitis Optica Drug Market Size by Type
7.2.1 Europe Neuromyelitis Optica Drug Market Size by Type (2019-2024)
7.2.2 Europe Neuromyelitis Optica Drug Market Size by Type (2025-2030)
7.2.3 Europe Neuromyelitis Optica Drug Market Share by Type (2019-2030)
7.3 Europe Neuromyelitis Optica Drug Market Size by Application
7.3.1 Europe Neuromyelitis Optica Drug Market Size by Application (2019-2024)
7.3.2 Europe Neuromyelitis Optica Drug Market Size by Application (2025-2030)
7.3.3 Europe Neuromyelitis Optica Drug Market Share by Application (2019-2030)
7.4 Europe Neuromyelitis Optica Drug Market Size by Country
7.4.1 Europe Neuromyelitis Optica Drug Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Neuromyelitis Optica Drug Market Size by Country (2019-2024)
7.4.3 Europe Neuromyelitis Optica Drug Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Neuromyelitis Optica Drug Market Size (2019-2030)
8.2 China Neuromyelitis Optica Drug Market Size by Type
8.2.1 China Neuromyelitis Optica Drug Market Size by Type (2019-2024)
8.2.2 China Neuromyelitis Optica Drug Market Size by Type (2025-2030)
8.2.3 China Neuromyelitis Optica Drug Market Share by Type (2019-2030)
8.3 China Neuromyelitis Optica Drug Market Size by Application
8.3.1 China Neuromyelitis Optica Drug Market Size by Application (2019-2024)
8.3.2 China Neuromyelitis Optica Drug Market Size by Application (2025-2030)
8.3.3 China Neuromyelitis Optica Drug Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Neuromyelitis Optica Drug Market Size (2019-2030)
9.2 Asia Neuromyelitis Optica Drug Market Size by Type
9.2.1 Asia Neuromyelitis Optica Drug Market Size by Type (2019-2024)
9.2.2 Asia Neuromyelitis Optica Drug Market Size by Type (2025-2030)
9.2.3 Asia Neuromyelitis Optica Drug Market Share by Type (2019-2030)
9.3 Asia Neuromyelitis Optica Drug Market Size by Application
9.3.1 Asia Neuromyelitis Optica Drug Market Size by Application (2019-2024)
9.3.2 Asia Neuromyelitis Optica Drug Market Size by Application (2025-2030)
9.3.3 Asia Neuromyelitis Optica Drug Market Share by Application (2019-2030)
9.4 Asia Neuromyelitis Optica Drug Market Size by Region
9.4.1 Asia Neuromyelitis Optica Drug Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Neuromyelitis Optica Drug Market Size by Region (2019-2024)
9.4.3 Asia Neuromyelitis Optica Drug Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Type
10.2.1 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Application
10.3.1 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Country
10.4.1 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuromyelitis Optica Drug Introduction
11.1.4 Pfizer Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.1.5 Pfizer Recent Developments
11.2 Fresenius
11.2.1 Fresenius Company Details
11.2.2 Fresenius Business Overview
11.2.3 Fresenius Neuromyelitis Optica Drug Introduction
11.2.4 Fresenius Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.2.5 Fresenius Recent Developments
11.3 Teva
11.3.1 Teva Company Details
11.3.2 Teva Business Overview
11.3.3 Teva Neuromyelitis Optica Drug Introduction
11.3.4 Teva Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.3.5 Teva Recent Developments
11.4 Sandoz
11.4.1 Sandoz Company Details
11.4.2 Sandoz Business Overview
11.4.3 Sandoz Neuromyelitis Optica Drug Introduction
11.4.4 Sandoz Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.4.5 Sandoz Recent Developments
11.5 Intas
11.5.1 Intas Company Details
11.5.2 Intas Business Overview
11.5.3 Intas Neuromyelitis Optica Drug Introduction
11.5.4 Intas Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.5.5 Intas Recent Developments
11.6 Gyjtrs
11.6.1 Gyjtrs Company Details
11.6.2 Gyjtrs Business Overview
11.6.3 Gyjtrs Neuromyelitis Optica Drug Introduction
11.6.4 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.6.5 Gyjtrs Recent Developments
11.7 NANG KUANG
11.7.1 NANG KUANG Company Details
11.7.2 NANG KUANG Business Overview
11.7.3 NANG KUANG Neuromyelitis Optica Drug Introduction
11.7.4 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.7.5 NANG KUANG Recent Developments
11.8 Tianjin Kingyork
11.8.1 Tianjin Kingyork Company Details
11.8.2 Tianjin Kingyork Business Overview
11.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Introduction
11.8.4 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.8.5 Tianjin Kingyork Recent Developments
11.9 Baxter
11.9.1 Baxter Company Details
11.9.2 Baxter Business Overview
11.9.3 Baxter Neuromyelitis Optica Drug Introduction
11.9.4 Baxter Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.9.5 Baxter Recent Developments
11.10 CSL
11.10.1 CSL Company Details
11.10.2 CSL Business Overview
11.10.3 CSL Neuromyelitis Optica Drug Introduction
11.10.4 CSL Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.10.5 CSL Recent Developments
11.11 Grifols
11.11.1 Grifols Company Details
11.11.2 Grifols Business Overview
11.11.3 Grifols Neuromyelitis Optica Drug Introduction
11.11.4 Grifols Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.11.5 Grifols Recent Developments
11.12 Octapharma
11.12.1 Octapharma Company Details
11.12.2 Octapharma Business Overview
11.12.3 Octapharma Neuromyelitis Optica Drug Introduction
11.12.4 Octapharma Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.12.5 Octapharma Recent Developments
11.13 CBOP
11.13.1 CBOP Company Details
11.13.2 CBOP Business Overview
11.13.3 CBOP Neuromyelitis Optica Drug Introduction
11.13.4 CBOP Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.13.5 CBOP Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Glucocorticoids
    Table 3. Key Players of Immunotherapies
    Table 4. Key Players of Others
    Table 5. Global Neuromyelitis Optica Drug Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 6. Global Neuromyelitis Optica Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Neuromyelitis Optica Drug Market Size by Region (2019-2024) & (US$ Million)
    Table 8. Global Neuromyelitis Optica Drug Market Share by Region (2019-2024)
    Table 9. Global Neuromyelitis Optica Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 10. Global Neuromyelitis Optica Drug Market Share by Region (2025-2030)
    Table 11. Neuromyelitis Optica Drug Market Trends
    Table 12. Neuromyelitis Optica Drug Market Drivers
    Table 13. Neuromyelitis Optica Drug Market Challenges
    Table 14. Neuromyelitis Optica Drug Market Restraints
    Table 15. Global Neuromyelitis Optica Drug Revenue by Players (2019-2024) & (US$ Million)
    Table 16. Global Neuromyelitis Optica Drug Revenue Share by Players (2019-2024)
    Table 17. Global Top Neuromyelitis Optica Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2023)
    Table 18. Global Neuromyelitis Optica Drug Industry Ranking 2022 VS 2023 VS 2024
    Table 19. Global 5 Largest Players Market Share by Neuromyelitis Optica Drug Revenue (CR5 and HHI) & (2019-2024)
    Table 20. Global Key Players of Neuromyelitis Optica Drug, Headquarters and Area Served
    Table 21. Global Key Players of Neuromyelitis Optica Drug, Product and Application
    Table 22. Global Key Players of Neuromyelitis Optica Drug, Product and Application
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (US$ Million)
    Table 25. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2019-2024)
    Table 26. Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 27. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2025-2030)
    Table 28. Global Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (US$ Million)
    Table 29. Global Neuromyelitis Optica Drug Revenue Share by Application (2019-2024)
    Table 30. Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 31. Global Neuromyelitis Optica Drug Revenue Share by Application (2025-2030)
    Table 32. North America Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (US$ Million)
    Table 33. North America Neuromyelitis Optica Drug Market Size by Type (2025-2030) & (US$ Million)
    Table 34. North America Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (US$ Million)
    Table 35. North America Neuromyelitis Optica Drug Market Size by Application (2025-2030) & (US$ Million)
    Table 36. North America Neuromyelitis Optica Drug Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 37. North America Neuromyelitis Optica Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 38. North America Neuromyelitis Optica Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 39. Europe Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (US$ Million)
    Table 40. Europe Neuromyelitis Optica Drug Market Size by Type (2025-2030) & (US$ Million)
    Table 41. Europe Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (US$ Million)
    Table 42. Europe Neuromyelitis Optica Drug Market Size by Application (2025-2030) & (US$ Million)
    Table 43. Europe Neuromyelitis Optica Drug Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Europe Neuromyelitis Optica Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Europe Neuromyelitis Optica Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 46. China Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (US$ Million)
    Table 47. China Neuromyelitis Optica Drug Market Size by Type (2025-2030) & (US$ Million)
    Table 48. China Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (US$ Million)
    Table 49. China Neuromyelitis Optica Drug Market Size by Application (2025-2030) & (US$ Million)
    Table 50. Asia Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (US$ Million)
    Table 51. Asia Neuromyelitis Optica Drug Market Size by Type (2025-2030) & (US$ Million)
    Table 52. Asia Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (US$ Million)
    Table 53. Asia Neuromyelitis Optica Drug Market Size by Application (2025-2030) & (US$ Million)
    Table 54. Asia Neuromyelitis Optica Drug Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 55. Asia Neuromyelitis Optica Drug Market Size by Region (2019-2024) & (US$ Million)
    Table 56. Asia Neuromyelitis Optica Drug Market Size by Region (2025-2030) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Type (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Application (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 62. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 64. Pfizer Company Details
    Table 65. Pfizer Business Overview
    Table 66. Pfizer Neuromyelitis Optica Drug Product
    Table 67. Pfizer Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 68. Pfizer Recent Developments
    Table 69. Fresenius Company Details
    Table 70. Fresenius Business Overview
    Table 71. Fresenius Neuromyelitis Optica Drug Product
    Table 72. Fresenius Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 73. Fresenius Recent Developments
    Table 74. Teva Company Details
    Table 75. Teva Business Overview
    Table 76. Teva Neuromyelitis Optica Drug Product
    Table 77. Teva Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 78. Teva Recent Developments
    Table 79. Sandoz Company Details
    Table 80. Sandoz Business Overview
    Table 81. Sandoz Neuromyelitis Optica Drug Product
    Table 82. Sandoz Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 83. Sandoz Recent Developments
    Table 84. Intas Company Details
    Table 85. Intas Business Overview
    Table 86. Intas Neuromyelitis Optica Drug Product
    Table 87. Intas Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 88. Intas Recent Developments
    Table 89. Gyjtrs Company Details
    Table 90. Gyjtrs Business Overview
    Table 91. Gyjtrs Neuromyelitis Optica Drug Product
    Table 92. Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 93. Gyjtrs Recent Developments
    Table 94. NANG KUANG Company Details
    Table 95. NANG KUANG Business Overview
    Table 96. NANG KUANG Neuromyelitis Optica Drug Product
    Table 97. NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 98. NANG KUANG Recent Developments
    Table 99. Tianjin Kingyork Company Details
    Table 100. Tianjin Kingyork Business Overview
    Table 101. Tianjin Kingyork Neuromyelitis Optica Drug Product
    Table 102. Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 103. Tianjin Kingyork Recent Developments
    Table 104. Baxter Company Details
    Table 105. Baxter Business Overview
    Table 106. Baxter Neuromyelitis Optica Drug Product
    Table 107. Baxter Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 108. Baxter Recent Developments
    Table 109. CSL Company Details
    Table 110. CSL Business Overview
    Table 111. CSL Neuromyelitis Optica Drug Product
    Table 112. CSL Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 113. CSL Recent Developments
    Table 114. Grifols Company Details
    Table 115. Grifols Business Overview
    Table 116. Grifols Neuromyelitis Optica Drug Product
    Table 117. Grifols Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 118. Grifols Recent Developments
    Table 119. Octapharma Company Details
    Table 120. Octapharma Business Overview
    Table 121. Octapharma Neuromyelitis Optica Drug Product
    Table 122. Octapharma Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 123. Octapharma Recent Developments
    Table 124. CBOP Company Details
    Table 125. CBOP Business Overview
    Table 126. CBOP Neuromyelitis Optica Drug Product
    Table 127. CBOP Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 128. CBOP Recent Developments
    Table 129. Research Programs/Design for This Report
    Table 130. Key Data Information from Secondary Sources
    Table 131. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Neuromyelitis Optica Drug Market Share by Type: 2023 VS 2030
    Figure 3. Glucocorticoids Features
    Figure 4. Immunotherapies Features
    Figure 5. Others Features
    Figure 6. Global Neuromyelitis Optica Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 7. Global Neuromyelitis Optica Drug Market Share by Application: 2023 VS 2030
    Figure 8. Acute Attack Case Studies
    Figure 9. Remission Prophylactic Treatment Case Studies
    Figure 10. Neuromyelitis Optica Drug Report Years Considered
    Figure 11. Global Neuromyelitis Optica Drug Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 12. Global Neuromyelitis Optica Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Neuromyelitis Optica Drug Market Share by Region: 2023 VS 2030
    Figure 14. Global Neuromyelitis Optica Drug Market Share by Players in 2023
    Figure 15. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2023)
    Figure 16. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Drug Revenue in 2023
    Figure 17. North America Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 18. North America Neuromyelitis Optica Drug Market Share by Type (2019-2030)
    Figure 19. North America Neuromyelitis Optica Drug Market Share by Application (2019-2030)
    Figure 20. North America Neuromyelitis Optica Drug Market Share by Country (2019-2030)
    Figure 21. United States Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Canada Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Europe Neuromyelitis Optica Drug Market Size YoY (2019-2030) & (US$ Million)
    Figure 24. Europe Neuromyelitis Optica Drug Market Share by Type (2019-2030)
    Figure 25. Europe Neuromyelitis Optica Drug Market Share by Application (2019-2030)
    Figure 26. Europe Neuromyelitis Optica Drug Market Share by Country (2019-2030)
    Figure 27. Germany Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. France Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. U.K. Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Italy Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Russia Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Nordic Countries Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. China Neuromyelitis Optica Drug Market Size YoY (2019-2030) & (US$ Million)
    Figure 34. China Neuromyelitis Optica Drug Market Share by Type (2019-2030)
    Figure 35. China Neuromyelitis Optica Drug Market Share by Application (2019-2030)
    Figure 36. Asia Neuromyelitis Optica Drug Market Size YoY (2019-2030) & (US$ Million)
    Figure 37. Asia Neuromyelitis Optica Drug Market Share by Type (2019-2030)
    Figure 38. Asia Neuromyelitis Optica Drug Market Share by Application (2019-2030)
    Figure 39. Asia Neuromyelitis Optica Drug Market Share by Region (2019-2030)
    Figure 40. Japan Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. South Korea Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. China Taiwan Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Southeast Asia Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. India Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Australia Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size YoY (2019-2030) & (US$ Million)
    Figure 47. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Share by Type (2019-2030)
    Figure 48. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Share by Application (2019-2030)
    Figure 49. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Share by Country (2019-2030)
    Figure 50. Brazil Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 51. Mexico Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Turkey Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Saudi Arabia Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Israel Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. GCC Countries Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Pfizer Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 57. Fresenius Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 58. Teva Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 59. Sandoz Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 60. Intas Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 61. Gyjtrs Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 62. NANG KUANG Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 63. Tianjin Kingyork Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 64. Baxter Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 65. CSL Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 66. Grifols Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 67. Octapharma Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 68. CBOP Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 69. Bottom-up and Top-down Approaches for This Report
    Figure 70. Data Triangulation
    Figure 71. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure

SIMILAR REPORTS